 | • レポートコード：MRC2303H011 • 出版社/出版日：360iResearch / 2022年10月11日 • レポート形態：英語、PDF、239ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、2021年に181.2億ドルであった世界の高コレステロール血症治療薬市場規模が2022年に191.4億ドルとなり、今後は年平均5.90％成長して2027年までに255.6億ドルに達すると予測しています。当書は、高コレステロール血症治療薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、作用機序別（胆汁酸捕捉剤、フィブリン酸誘導体、HMG - CoAレダクターゼ阻害剤、ニコチン酸）分析、疾患種類別（FH、非FH）分析、薬剤分類別（非スタチン、スタチン）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめております。なお、当書には、Abbvie Inc.、Alnylam Pharmaceuticals Inc.、Amarin Corporation、Amgen Inc.、AstraZeneca PLC、AtheroNova Inc.、Aurobindo Pharma Limited、Cipla Limited、Daiichi Sankyo Company, Limited、Dr. Reddy's Laboratories Ltd、Eli Lilly and Companyなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の高コレステロール血症治療薬市場規模：作用機序別 - 胆汁酸捕捉剤の市場規模 - フィブリン酸誘導体の市場規模 - HMG - CoAレダクターゼ阻害剤の市場規模 - ニコチン酸の市場規模 ・世界の高コレステロール血症治療薬市場規模：疾患種類別 - FHにおける市場規模 - 非FHにおける市場規模 ・世界の高コレステロール血症治療薬市場規模：薬剤分類別 - 非スタチン系薬品の市場規模 - スタチン系薬品の市場規模 ・世界の高コレステロール血症治療薬市場規模：地域別 - 南北アメリカの高コレステロール血症治療薬市場規模 アメリカの高コレステロール血症治療薬市場規模 カナダの高コレステロール血症治療薬市場規模 ブラジルの高コレステロール血症治療薬市場規模 ... - アジア太平洋の高コレステロール血症治療薬市場規模 日本の高コレステロール血症治療薬市場規模 中国の高コレステロール血症治療薬市場規模 インドの高コレステロール血症治療薬市場規模 韓国の高コレステロール血症治療薬市場規模 台湾の高コレステロール血症治療薬市場規模 ... - ヨーロッパ/中東/アフリカの高コレステロール血症治療薬市場規模 イギリスの高コレステロール血症治療薬市場規模 ドイツの高コレステロール血症治療薬市場規模 フランスの高コレステロール血症治療薬市場規模 ロシアの高コレステロール血症治療薬市場規模 ... - その他地域の高コレステロール血症治療薬市場規模 ・競争状況 ・企業情報 |
The Global Hypercholesterolemia Drug Market size was estimated at USD 18.12 billion in 2021 and expected to reach USD 19.14 billion in 2022, and is projected to grow at a CAGR 5.90% to reach USD 25.56 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Hypercholesterolemia Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Mechanism of Action, the market was studied across Bile Acid Sequestrants, Fibric Acid Derivatives, HMG-CoA Reductase Inhibitors, and Nicotinic Acid.
Based on Type of Disease, the market was studied across FH and Non-FH.
Based on Drug Class, the market was studied across Non-statins and Statins.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Hypercholesterolemia Drug market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hypercholesterolemia Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hypercholesterolemia Drug Market, including Abbvie Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Amgen Inc., AstraZeneca PLC, AtheroNova Inc., Aurobindo Pharma Limited, Cipla Limited, Daiichi Sankyo Company, Limited, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, Esperion Therapeutics, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ionis Pharmaceuticals Inc., Merck & Co Inc., Mylan NV, Novartis AG, Pfizer Inc., Sanofi S.A., and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Hypercholesterolemia Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hypercholesterolemia Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hypercholesterolemia Drug Market?
4. What is the competitive strategic window for opportunities in the Global Hypercholesterolemia Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Hypercholesterolemia Drug Market?
6. What is the market share of the leading vendors in the Global Hypercholesterolemia Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Hypercholesterolemia Drug Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of heart disorders worldwide
5.1.1.2. Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
5.1.1.3. Proliferation in healthcare expenditure by consumers and on infrastructure from private and public organizations
5.1.2. Restraints
5.1.2.1. Availability of alternative substitutes in the market
5.1.2.2. Consumer awareness on healthy and fit diet
5.1.3. Opportunities
5.1.3.1. Technological advancements in introduction of novel drugs
5.1.3.2. Rising utilization of combination therapies across regions
5.1.4. Challenges
5.1.4.1. Competition from generic versions of branded drugs
5.2. Cumulative Impact of COVID-19
6. Hypercholesterolemia Drug Market, by Mechanism of Action
6.1. Introduction
6.2. Bile Acid Sequestrants
6.3. Fibric Acid Derivatives
6.4. HMG-CoA Reductase Inhibitors
6.5. Nicotinic Acid
7. Hypercholesterolemia Drug Market, by Type of Disease
7.1. Introduction
7.2. FH
7.3. Non-FH
8. Hypercholesterolemia Drug Market, by Drug Class
8.1. Introduction
8.2. Non-statins
8.3. Statins
9. Americas Hypercholesterolemia Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Hypercholesterolemia Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Hypercholesterolemia Drug Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbvie Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Alnylam Pharmaceuticals Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Amarin Corporation
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Amgen Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. AstraZeneca PLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. AtheroNova Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Aurobindo Pharma Limited
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cipla Limited
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Daiichi Sankyo Company, Limited
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Dr. Reddy’s Laboratories Ltd
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eli Lilly and Company
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Esperion Therapeutics, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. GlaxoSmithKline PLC
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Hikma Pharmaceuticals PLC
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Ionis Pharmaceuticals Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck & Co Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Mylan NV
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Novartis AG
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Pfizer Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Sanofi S.A.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Teva Pharmaceutical Industries Ltd.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing